AzTrials
AzTrials

Nasolacrimal Duct ObstructionPhase 4NCT00784992

A Comparison of Endonasal Dacryocystorhinostomy With and Without Silicone Tubes

A Phase 4 study testing Endonasal dacryocystorhinostomy in people with Nasolacrimal Duct Obstruction, run by University of British Columbia at 2 sites in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Aim of study is to investigate whether the use of silicone tubes in endonasal DCR surgery increases the success rate and / or complication rate compared to surgery without tubes. Read more about this study

Who is it for?
Ages 16 years and olderHealthy volunteers can take part
Conditions the study is for
Nasolacrimal Duct Obstruction
What is being tested?
Endonasal dacryocystorhinostomy
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
200 participants
Where
2 sitesCanada
Study dates
Nov 2008to 2 Jun 2016
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 16 years and older
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Who may be able to join

  • Adult patients (> 16 years) undergoing primary DCR for NLDO who have given fully informed consent to be in the trial

Who cannot join

  • Age less than 16 years
  • Previous ipsilateral DCR or nasal surgery
  • Canalicular disease

Trial locations and contacts

2 sites in 1 country.

Canada2 sites
  • Eye Care Centre (Clinic)

    Vancouver, British Columbia

  • VGH/UBC (Operating Rooms)

    Vancouver, British Columbia

Other trials in Canada

About this study

Official title: A Randomised Controlled Trial to Compare Success and Complication Rates in Endonasal Dacryocystorhinostomy Surgery With and Without Silicone Tubes

Aim of study is to investigate whether the use of silicone tubes in endonasal DCR surgery increases the success rate and / or complication rate compared to surgery without tubes.

Read the detailed description

Dacryocystorhinostomy (DCR) is the treatment of choice for epiphora due to nasolacrimal duct obstruction. A passage is created between the lacrimal sac and nasal cavity by removing the layers of bone and mucosa between them. It can be performed via an external (transcutaneous) or endonasal route with equivalent success rates.[1] In order to prevent restenosis of the ostium, silicone tubes are often used to maintain the patency of the newly-created fistula. The tubes are removed between 6 weeks and 3 months post-operatively.

Problems associated with tubes include granuloma formation with secondary infection or adhesions, canalicular lacerations, allergic reaction to the silastic, and discomfort.

There are a number of reports of DCR surgery without tubes which demonstrate an equivalent success rate compared with surgery using tubes; however, these studies have been non-randomised, retrospective reviews.[2-6] The only prospective, randomised controlled study[7] had only 42 participants and did not state at which point during the surgery the randomisation was revealed; unless the allocation occurs after the ostium has been completed there is the risk of bias since the surgeon may (consciously or inadvertently) create a larger ostium in cases where no tubes are to be used.

The purpose of this study is to perform a prospective, randomised controlled study to assess whether the use of tubes affect the long-term success of DCR.

Hypothesis Silicone tubing does not improve success rate of endonasal DCR surgery.

Justification There is a dearth of evidence in the literature from well-conducted studies on the merits of tubes versus no tubes in DCR surgery. Since there are several potential problems with tubes outlined above, and since performing surgery with tubes adds to the cost and duration of surgery, it would benefit patients and healthcare providers to know whether they increase DCR success rate.

The standard surgical technique for endonasal DCR has been described by the principle investigator.[1] The identical procedure would be performed in both groups with the exception that half the patients would have tubes inserted, and half would not.

Objectives To assess functional and anatomical success rates of endonasal DCR surgery with and without silicone tubes.

Research Method Prospective, randomised, controlled, interventional trial.

Statistical analysis The primary end point will be functional success, determined by patient-reported symptoms. This will be assessed a minimum of six months post-operatively. In patients with tubes these will be removed at 3 months post-operatively.

The operation will be considered successful if the patient is free of symptoms of a watering eye. It will be considered partially successful if the patient has noticeable improvement but still may experience tearing under certain situations. The operation will be deemed a failure if the patient continues to have symptoms that are no better or worse than pre-operatively.

The secondary end point will be anatomical success, as measured by patency of nasolacrimal irrigation at 6 months post-operatively. In patients with tubes these will be removed at 3 months post-operatively. The operation will be considered successful if there is free flow on irrigation with no reflux. It will be considered partially successful if the nasolacrimal duct is patent but there is more than 50% reflux as assessed by an experienced oculoplastic surgeon. It will be considered a failure if there is more than 50% reflux.

The secondary end point will be anatomical success, as measured by patency of nasolacrimal irrigation at 6 months post-operatively.

Statistical analysis planned From a previous study by the PI[1] (and also from numerous other studies in the ophthalmic literature) the baseline success rate for endonasal DCR with tubes is 90%. The current trial is a non-inferiority study, ie to demonstrate that surgery without tubes is not inferior to surgery with tubes.

In order to demonstrate non-inferiority, the recommended approach is to pre-specify a margin of non-inferiority in the protocol. After study completion, a two-sided 95% confidence interval for the true difference between the two agents will be constructed.[8]

Planned sample size A sample size of 200 (100 participants in each arm of the trial) is expected to give a 95% confidence interval of width of approximately 0.15 ie +/- 7.5% around the estimated difference in success rates.

References

  1. Dolman PJ. Comparison of external dacryocystorhinostomy with nonlaser endonasal dacryocystorhinostomy. Ophthalmology. 2003 Jan;110(1):78-84
  2. Smirnov G, Tuomilehto H, Teräsvirta M, Nuutinen J, Seppä J. Silicone tubing after endoscopic dacryocystorhinostomy: is it necessary? Am J Rhinol. 2006 Nov-Dec;20(6):600-2
  3. Mortimore S, Banhegy GY, Lancaster JL, Karkanevatos A. Endoscopic dacryocystorhinostomy without silicone stenting. J R Coll Surg Edinb. 1999 Dec;44(6):371-3
  4. Kashkouli MB, Parvaresh M, Modarreszadeh M, Hashemi M, Beigi B. Factors affecting the success of external dacryocystorhinostomy. Orbit. 2003 Dec;22(4):247-55
  5. Beigi B, Westlake W, Chang B, Marsh C, Jacob J, Chatfield J. Dacryocystorhinostomy in south west England. Eye. 1998;12 ( Pt 3a):358-62.
  6. Unlü HH, Oztürk F, Mutlu C, Ilker SS, Tarhan S. Endoscopic dacryocystorhinostomy without stents. Auris Nasus Larynx. 2000 Jan;27(1):65-71
  7. Smirnov G, Tuomilehto H, Teräsvirta M, Nuutinen J, Seppä J. Silicone tubing is not necessary after primary endoscopic dacryocystorhinostomy: A prospective randomized study. Am J Rhinol 22, 214-217, 2008
  8. http://www.emea.europa.eu/pdfs/human/ewp/215899en.pdf
Being tested
Endonasal dacryocystorhinostomy
Keywords
NLDO, DCR, silicone tubes, stent
Medical subject headings
Lacrimal Duct Obstruction

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Endonasal dacryocystorhinostomyProcedure or surgery

    The standard dacryocystorhinostomy operation performed in this centre uses silicone tubes to stent open the newly created ostium between the lacrimal sac and the nasal cavity. However many surgeons in other departments / countries around the world perform the surgery without tubes. No large well-conducted RCT has been published comparing success rates / complication rates for the two techniques. For this study the control group is the arm which receives tubes (our standard procedure) and the 'interventional' group is the arm not receiving tubes.

    Details of the operative technique for endonasal DCR with tubes can be found in the following reference: Dolman PJ. Comparison of external dacryocystorhinostomy with nonlaser endonasal dacryocystorhinostomy. Ophthalmology. 2003 Jan;110(1):78-84. The group that will not receive tubes will undergo the same procedure except that the insertion of tubes will be omitted.

Study groups in NCT00784992
Study groupRoleWhat they receive
1No interventionEndonasal DCR with silicone tubes (this is the control group since it is the standard procedure / gold standard, although the evidence base for the use of tubes is lacking, hence the need for this trial)
2Active comparatorEndonasal DCR without silicone tubes (this is the 'intervention' arm)
Receives: Procedure: Endonasal dacryocystorhinostomy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The primary end point will be functional success, determined by patient-reported symptoms. This will be assessed a minimum of six months post-operatively. In patients with tubes these will be removed at 3 months post-operatively.

    Measured: 6 months

Secondary outcomes (1)
  1. The secondary end point will be anatomical success, as measured by patency of nasolacrimal irrigation at 6 months post-operatively. In patients with tubes these will be removed at 3 months post-operatively.

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Nov 2008 (estimated)
  2. Study startNov 2008
  3. Primary completion2 Jun 2016
  4. Study completion2 Jun 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
200 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00784992
Sponsor's protocol ID
H08-02025
Status last verified
Mar 2017
First submitted
4 Nov 2008
Last updated
3 Mar 2017
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Endonasal dacryocystorhinostomy in people with Nasolacrimal Duct Obstruction, run by University of British Columbia at 2 sites in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Mar 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The primary end point will be functional success, determined by patient-reported symptoms. This will be assessed a minimum of six months post-operatively. In patients with tubes these will be removed at 3 months post-operatively. (time frame: 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Mar 2017; AzTrials last refreshed its copy on 8 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in